Attovia Therapeutics Inc
NAS:ATTOHealth Technologynasdaq_composite$13.89+1.17%At closeAt close · Tue 20 Oct · ≈ AED 51.01 · Market cap $634.1M · Next earnings Wed 2 Dec
| USD millions | FY2024 | FY2025 |
|---|---|---|
| Revenue | 0.0 | 1.4 |
| Cost of revenue | 0.3 | 0.8 |
| Gross profit | (0.3) | 0.5 |
| Research & development | 33.9 | 54.2 |
| Operating expenses | 41.2 | 67.7 |
| Operating income | (41.6) | (67.2) |
| Interest expense | 0.0 | 0.0 |
| Interest income | 3.4 | 6.6 |
| Pre-tax income | (39.8) | (60.6) |
| Income tax | 0.0 | 0.0 |
| Net income | (45.0) | (60.9) |
| EPS, basic (per share) | (0.99) | (1.33) |
| EPS, diluted (per share) | (0.99) | (1.33) |
| EBITDA | (41.2) | (66.4) |
| Depreciation & amortization | 0.3 | 0.8 |
| Weighted average shares (shares) | 45,651,262 | 45,651,262 |
| Weighted average diluted shares (shares) | 45,651,262 | 45,651,262 |
| Gross margin | — | 40.4% |
| Operating margin | — | −4,974.7% |
| Net margin | — | −4,511.0% |
USD millionsUpdated Wed 2 Sep ·
ⓘ
Amounts are shown in the stated units; per-share amounts and shares are unscaled. Negative amounts are in brackets.
